


PRODUCT INFORMATION



Mozavaptan-d₆ Item No. 31321

CAS Registry No.: 2750534-83-7
Formal Name: N-[4-[[5-(dimethyl-d₆-amino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl]phenyl]-2-methyl-benzamide
MF: C₂₇H₂₃D₆N₃O₂
FW: 433.6
Chemical Purity: ≥98% (Mozavaptan)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₆); ≤1% d₀
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Mozavaptan-d₆ is intended for use as an internal standard for the quantification of mozavaptan (Item No. 16664) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Mozavaptan-d₆ is supplied as a solid. A stock solution may be made by dissolving the mozavaptan-d₆ in the solvent of choice, which should be purged with an inert gas. Mozavaptan-d₆ is soluble in DMSO and dimethyl formamide. Mozavaptan-d₆ is soluble in a 1:1 solution of acetonitrile:methanol.

Description

Mozavaptan is an orally bioavailable antagonist of vasopressin V₂ receptors (K_i = 9.42 nM in HeLa cells expressing the human receptor).^{1,2} It is selective for vasopressin V₂ over V₁ receptors (IC₅₀s = 14 and 1,200 nM, respectively) in radioligand binding assays using rat kidney and rat liver membranes that endogenously express high levels of vasopressin V₂ and V₁ receptors, respectively.¹ Mozavaptan (10-30 mg/kg, p.o.) increases urine volume and decreases urine osmolality, indicating aquaresis, in conscious rats. It reduces decreases in urine flow and increases in urine osmolality induced by arginine vasopressin (AVP; Item No. 24154) in anesthetized rats when administered intravenously at doses ranging from 10 to 100 µg/kg.

References

1. Yamamura, Y., Ogawa, H., Yamashita, H., *et al.* Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V₂ receptor antagonist. *Br. J. Pharmacol.* **105(4)**, 787-791 (1992).
2. Nakamura, S., Itoh, S., Fujiki, H., *et al.* Binding affinities of mozavaptan hydrochloride (OPC-31260) for vasopressin receptors. *Jap. Pharmacol. Ther.* **34(7)**, 827-834 (2006).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/26/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM